Executive remuneration in Australia’s health care and biotechnology sectors rose modestly in the last financial year, with a 7.2 per cent increase in total CEO pay, according to the 2025 ASX Health Care and Biotechnology Remuneration Report.
CEO pay rebounds across ASX health and biotech as boards balance pressure and retention
December 3, 2025 Australian BiotechBioPharmaDispatch Executive
Latest Video
New Stories
-
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News -
The value of looking back and the importance of seeing the 'smoke signals' on reform
January 8, 2026 - - Latest News -
Vaxxas appoints former global vaccines leader to head global commercialisation push
January 8, 2026 - - Australian Biotech -
Reform was justified because a committee prioritising clinical considerations was 'culturally' problematic
January 4, 2026 - - Latest News -
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 - - Australian Biotech


